{"id":775733,"date":"2023-08-04T19:58:26","date_gmt":"2023-08-04T23:58:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/"},"modified":"2023-08-04T19:58:26","modified_gmt":"2023-08-04T23:58:26","slug":"xortx-appoints-chief-financial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/","title":{"rendered":"XORTX Appoints Chief Financial Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CALGARY, Alberta, Aug.  04, 2023  (GLOBE NEWSWIRE) &#8212; XORTX Therapeutics Inc. (&#8220;<strong>XORTX<\/strong>&#8221; or the \u201c<strong>Company<\/strong>\u201d) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of James Fairbairn as Chief Financial Officer to replace Amar Keshri who left the Company\u2019s employ effective July 31, 2023. James Fairbairn was appointed Interim Chief Financial Officer on June 28, 2023.<\/p>\n<p align=\"justify\">James Fairbairn was the Company\u2019s Chief Financial Officer from November 2018 through July 2021. He has more than 30 years of experience with publicly-traded companies. He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and is an Institute-certified Director. Jim Fairbairn holds a B.A. from Western University.<\/p>\n<p align=\"justify\">\n        <strong>About XORTX Therapeutics Inc.<\/strong><br \/>\n        <br \/>XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus \/ COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RIF4zub5W78FTj4MTM2eI3Iu031moEZIKpEX0J69D0X61qLR_7lG4bqGBdYm2bscB_vVAEDvJkanfrPbwSNvrQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.xortx.com<\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: middle\">For more information, please contact:<\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle\">Allen Davidoff, CEO<br \/><a href=\"mailto:adavidoff@xortx.com\" rel=\"nofollow noopener\" target=\"_blank\">adavidoff@xortx.com<\/a>\u00a0or +1 403 455 7727<\/td>\n<td style=\"vertical-align: middle\">Nick Rigopulos, Director of Communications<br \/><a href=\"mailto:nick@alpineequityadv.com\" rel=\"nofollow noopener\" target=\"_blank\">nick@alpineequityadv.com<\/a>\u00a0or +1 617 901 0785<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"vertical-align: middle\">Media Inquiries, David Melamed, Ph.D.<br \/><a href=\"mailto:david.melamed@russopartnersllc.com\" rel=\"nofollow noopener\" target=\"_blank\">david.melamed@russopartnersllc.com<\/a>\u00a0or +1 212 845 4225\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <em>Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.<\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<br \/><\/strong>This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading \u201cRisk Factors\u201d in XORTX\u2019s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC&#8217;s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CmYgVPFaiwwRV77oYYOjI_EX7naetu6TgWprgN5XpPPygU6WWlA8N7BbXoFIiALhabRv0HHNk2zUaj9mFHEsjw==\" rel=\"nofollow noopener\" target=\"_blank\">www.sec.gov<\/a> (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CmYgVPFaiwwRV77oYYOjI3jech7f_XWQB-GKhKNatlZVa6F-2RvsUttDU246V_3L7bDmagrhd1b8UC0aus7lTg==\" rel=\"nofollow noopener\" target=\"_blank\">www.sedar.com<\/a>.<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/N2E0Y2NjYTMtNmZhYy00NTBjLWFlY2ItZmI0ZDI5M2FiOWRkLTExMDg4NTA=\/tiny\/XORTX-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) &#8212; XORTX Therapeutics Inc. (&#8220;XORTX&#8221; or the \u201cCompany\u201d) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of James Fairbairn as Chief Financial Officer to replace Amar Keshri who left the Company\u2019s employ effective July 31, 2023. James Fairbairn was appointed Interim Chief Financial Officer on June 28, 2023. James Fairbairn was the Company\u2019s Chief Financial Officer from November 2018 through July 2021. He has more than 30 years of experience with publicly-traded companies. He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and is an Institute-certified Director. Jim &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;XORTX Appoints Chief Financial Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-775733","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XORTX Appoints Chief Financial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XORTX Appoints Chief Financial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) &#8212; XORTX Therapeutics Inc. (&#8220;XORTX&#8221; or the \u201cCompany\u201d) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of James Fairbairn as Chief Financial Officer to replace Amar Keshri who left the Company\u2019s employ effective July 31, 2023. James Fairbairn was appointed Interim Chief Financial Officer on June 28, 2023. James Fairbairn was the Company\u2019s Chief Financial Officer from November 2018 through July 2021. He has more than 30 years of experience with publicly-traded companies. He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and is an Institute-certified Director. Jim &hellip; Continue reading &quot;XORTX Appoints Chief Financial Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-04T23:58:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"XORTX Appoints Chief Financial Officer\",\"datePublished\":\"2023-08-04T23:58:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/\"},\"wordCount\":475,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/\",\"name\":\"XORTX Appoints Chief Financial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=\",\"datePublished\":\"2023-08-04T23:58:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xortx-appoints-chief-financial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XORTX Appoints Chief Financial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XORTX Appoints Chief Financial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/","og_locale":"en_US","og_type":"article","og_title":"XORTX Appoints Chief Financial Officer - Market Newsdesk","og_description":"CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) &#8212; XORTX Therapeutics Inc. (&#8220;XORTX&#8221; or the \u201cCompany\u201d) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of James Fairbairn as Chief Financial Officer to replace Amar Keshri who left the Company\u2019s employ effective July 31, 2023. James Fairbairn was appointed Interim Chief Financial Officer on June 28, 2023. James Fairbairn was the Company\u2019s Chief Financial Officer from November 2018 through July 2021. He has more than 30 years of experience with publicly-traded companies. He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and is an Institute-certified Director. Jim &hellip; Continue reading \"XORTX Appoints Chief Financial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-04T23:58:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"XORTX Appoints Chief Financial Officer","datePublished":"2023-08-04T23:58:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/"},"wordCount":475,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/","name":"XORTX Appoints Chief Financial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=","datePublished":"2023-08-04T23:58:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg4ODAzOCM1NzM5MTUxIzIwOTcyNzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xortx-appoints-chief-financial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"XORTX Appoints Chief Financial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=775733"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775733\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=775733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=775733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=775733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}